Of particular concern are FDA 483s issued mainly by the U.S. Food and Drug Administration (FDA) for violations of current Good Manufacturing Practices (cGMP) Cosmetics facility design consultants in India, data integrity lapses, inadequate quality controls and associated issues. Such letters have serious implications — affecting market access, reputation, and compliance costs. https://sites.google.com/view/usfda-warning-letter-adroitix/home